WO2013013338A1 - Utilisation de substances ciblant la voie de signalisation gc-c dans le diagnostic et le traitement de maladies des neurones dopaminergiques mésencéphaliques - Google Patents

Utilisation de substances ciblant la voie de signalisation gc-c dans le diagnostic et le traitement de maladies des neurones dopaminergiques mésencéphaliques Download PDF

Info

Publication number
WO2013013338A1
WO2013013338A1 PCT/CN2011/001209 CN2011001209W WO2013013338A1 WO 2013013338 A1 WO2013013338 A1 WO 2013013338A1 CN 2011001209 W CN2011001209 W CN 2011001209W WO 2013013338 A1 WO2013013338 A1 WO 2013013338A1
Authority
WO
WIPO (PCT)
Prior art keywords
guanylate cyclase
mice
gene
dopamine
attention deficit
Prior art date
Application number
PCT/CN2011/001209
Other languages
English (en)
Chinese (zh)
Inventor
罗敏敏
龚蓉
丁澄
Original Assignee
北京生命科学研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 北京生命科学研究所 filed Critical 北京生命科学研究所
Priority to PCT/CN2011/001209 priority Critical patent/WO2013013338A1/fr
Publication of WO2013013338A1 publication Critical patent/WO2013013338A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Definitions

  • the present invention relates to the use of a substance targeting guanylate cyclase-C (GC-C) and protein kinase G (PKG) signaling pathways, in particular to the use of GC-C and protein kinase G (PKG) signaling pathways.
  • GC-C guanylate cyclase-C
  • PKG protein kinase G
  • the midbrain dopamine system is a very important neurotransmitter system.
  • Dopamine neurons distributed in the ventral tegmental area (VTA) and basal substantia nigra (SNc) of the midbrain project their axons to the forebrain and release dopamine to regulate many important behavioral processes such as exercise, cognition and learning.
  • VTA ventral tegmental area
  • SNc basal substantia nigra
  • Drug addiction is thought to be primarily related to activities from VTA to Nucleus Accumbens [References: Cornish, JL and PW alivas, Glutamate transmission in the nucleus accumbens mediates relapse in cocaine addiction. J Neurosci, 2000. 20(15): RC89. and Di Chiara, G., Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res, 2002. 137(1-2): 75-1 14.].
  • Receptor agonists and blockers corresponding to this variety of dopamine are used to treat diseases such as Parkinson's disease, schizophrenia, and attention deficit hyperactivity disorder [Emilien, G., et al" Dopamine receptors— Pharmacol Ther, 1999. 84(2): 133-156.] Studying how dopaminergic neurons are selectively regulated, not only helps us understand the neurobiological mechanisms of behavioral control And can provide ideas for finding more effective ways to treat mental illness.
  • GC Guanylate cyclase
  • Soluble guanylate cyclases are distributed in the cytosol and they can be activated by the small gas molecules nitric oxide and carbon monoxide. These small molecules can freely cross the cell membrane.
  • the guanylate cyclases on the membrane are transmembrane proteins, most of which are activated by extracellular signals.
  • GC-C Guanylate cyclase C belongs to guanylate cyclization on the membrane
  • the enzyme family is widely believed to be abundantly expressed in the small intestine of mammals, including humans [Miwatani, T. Amino-acid sequence of a heat-stable enterotoxin produced by human enterotoxigenic Escherichia coli. Eur. J. Biochem. 129, 257-263.] .
  • the gene sequence and amino acid sequence of GC-C were first determined by Schulz et al. [Schula S, et al. Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell, 1990. 63(5): 941-948.].
  • guanylate cyclase C Activation of guanylate cyclase C increases intracellular cGMP levels.
  • GC-C is also a key receptor for the intestinal hormones guanylin (G) and uroguanylin (UG) [Reference: Currie, MG, et al., Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA, 1992. 89(3): 947-951. and Hamra, FK, et al., Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA, 1993.
  • STa is a major cause of acute secretory diarrhea [Schulz, S., et al., Guanylyl cyclase is a heat-stable enterotoxin receptor. Cell, 1990. 63(5): 941-948.].
  • GC-C has been shown to be involved in the mediation of water and salt in the gut.
  • GC-C knockout mice can survive, fertile or even be physiologically healthy, and they exhibit significantly normal intestinal water regulation and body weight under different food and salt intake conditions [Reference: Mann, EA, et al., Mice lacking the guanylyl cyclase C receptor are resistant to STa-induced intestinal secretion. Biochem Biophys Res Commun, 1997. 239(2): 463-466. and Schulz, S., et al., Disruption of The guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. J Clin Invest, 1997. 100(6): 1590-1595.].
  • guanylate cyclase on the membrane is involved in behavioral regulation in the nematode [Tsunozaki, M., SH Chalasani, and CI Bargmann, A behavioral switch: cGMP and PKC signaling in olfactory neurons reverses odor preference in C. elegans. Neuron, 2008. 59(6): 959-971.], and the cGMP signaling pathway is also thought to be involved in important behavioral and physiological regulation in multiple species [References: Lucas, KA, et al., Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev, 2000. 52(3): 375-414.
  • ADHD Attention deficit hyperactivity disorder
  • the object of the present invention is to provide a substance targeting a guanylate cyclase-C (GC-C) and protein kinase G (PKG) signaling pathway, in particular to GC-C and protein kinase G (PKG).
  • GC-C guanylate cyclase-C
  • PKG protein kinase G
  • the substance that activates guanylate cyclase C is guanylin or uroguanylin.
  • guanylate cyclase C knockout mice for screening for products for the prevention and/or treatment of diseases associated with the midbrain dopamine system is also within the scope of the present invention.
  • the disease associated with the midbrain dopamine system may be human attention deficit hyperactivity disorder, schizophrenia, Parkinson's disease or drug addiction.
  • a GC-C knockout mouse exhibiting a behavioral defect as attention deficit hyperactivity disorder is used as an animal model of attention deficit hyperactivity disorder.
  • Another object of the present invention is to provide an animal model of attention deficit hyperactivity disorder, the animal model being a bird A mammal in which the nucleotide cyclase C gene is knocked out.
  • the method for constructing the animal model of attention deficit hyperactivity disorder is also within the scope of the present invention, and the method comprises the steps of: knocking out the guanylate cyclase C gene in the mammal of interest, and obtaining the guanylate cyclase
  • the animal in which the C gene is knocked out is an animal model of attention deficit hyperactivity disorder.
  • the method of knocking out the guanylate cyclase C gene in a mammal of interest is to exclude or replace the gene encoding the guanylate cyclase C in the mammal of interest.
  • the animal in which the guanylate cyclase C gene is knocked out can be prepared according to the following method: knocking out the guanylate cyclase c gene in ex vivo embryonic stem cells, and then guanylate cyclase C gene
  • the knockout embryonic stem cells are implanted into mouse blastocyst stage embryos, and finally transferred into the same mammalian uterus, and the born F1 mice are self-crossed to produce guanylate cyclase C gene knockout animals.
  • the mammal can be a mouse, rat, rabbit, monkey, pig or chicken. In a specific embodiment of the invention, the mammal is a mouse.
  • GC-C When GC-C is activated, it produces a large number of intracellular second messengers cGMP, which can effectively activate protein kinase G (PKG) to produce a series of intracellular effects.
  • PKG protein kinase G
  • the agonist of the GC-C/PKG signaling pathway is specifically an activator 8-Br-cGMP which is a protein kinase G; the inhibitor of the GC-C/PKG signaling pathway acts on Protein kinase G regulatory subunit inhibitor Rp-8-pCPT-cGMPS or an inhibitor of the functional subunit of protein kinase G KT5823; the disease associated with the midbrain dopamine system is attention deficit hyperactivity disorder, schizophrenia Symptoms, Parkinson's disease or drug addiction.
  • a GC-C knockout mouse exhibiting a behavioral defect as an attention deficit hyperactivity disorder is used as an animal model of attention deficit hyperactivity disorder.
  • Still another object of the present invention is to protect the use of a substance which detects the integrity of the guanylate cyclase C gene and the expression level of this protein in the preparation of a diagnostic or auxiliary diagnostic attention deficit hyperactivity disorder agent.
  • Detection of the integrity of the guanylate cyclase C gene can be accomplished by sequencing the genome or GC-C gene of ADHD patients or potential patients.
  • the substance for detecting the expression level of guanylate cyclase C may be an antibody against guanylate cyclase C (such as a monoclonal antibody or a polyclonal antibody) or an RNA hybridization encoding a ubiquitin cyclase C RNA.
  • a needle when detecting the expression level of guanylate cyclase C in a sample to be tested with an antibody against guanylate cyclase C or an RNA hybridization probe encoding guanylate cyclase C RNA, if The expression level of guanylate cyclase C in the sample is lower than the normal expression level of the organism or does not express guanylate cyclase C at all, suggesting that the sample to be tested may be derived from an organism with attention deficit hyperactivity disorder. If necessary, combined with other clinical diagnostic criteria for attention deficit hyperactivity disorder can be diagnosed.
  • Figure 1 shows GC-C expression in dopamine neurons in VTA/SNc.
  • A GC-C mRNA signal obtained by in situ hybridization.
  • B The signal of TH on the same brain slice.
  • C is the coincidence of A and B.
  • DF Double immunostaining showed GC-C (red) expression in midbrain dopamine cells containing the TH signal (green).
  • GI High magnification shows that GC-C is expressed on the cell bodies and dendrites in midbrain dopamine neurons.
  • Figure 2 shows GC-C in situ hybridization.
  • A GC-C in situ hybridization signal in the midbrain of wild-type mice.
  • B GC-C in situ hybridization signal in the midbrain of GC-C knockout mice.
  • FIG. 3 shows that in TH-GFP transgenic mice, GC-C was expressed on VTA/SNc cells containing green fluorescent protein (GFP) fluorescence.
  • A-F At the midbrain site, cells immunostained by GC-C and cells containing GFP in TH-GFP transgenic mice exhibited similar patterns.
  • A GC-C immunostaining (red).
  • B GFP cells are in the same position as shown in A.
  • C The coincidence of A and B.
  • D-F The area inside the dotted line box in (A-C) shown at high magnification.
  • FIG. 4 shows that in TH-GFP transgenic mice, GC-C was not expressed in dopamine neurons located in the hypothalamus (A) GC-C immunostaining (red). (B) GFP cells are in the same position as shown in A.
  • Figure 5 shows that electrophysiological properties of midbrain dopamine neurons cannot be affected by GC-C activation.
  • the comparison indicates a system without G and UG. Where G/UG means G or UG.
  • FIG. 6 shows that the reaction mediated by the ionotropic glutamate cyclase is not changed after GC-C activation.
  • A-D G/UG does not significantly alter the fast excitatory postsynaptic current caused by electrical stimulation.
  • A-C exemplified the absence of significant changes in post-synaptic excitatory currents in a midbrain dopaminergic nerve cell.
  • E-G G/UG does not significantly alter the inward current caused by AMPA stimulation.
  • E-F An exemplary demonstration of a midbrain dopamine neuron was added to G without significant changes in AMPA current.
  • Figure 7 shows that GC-C activation does not affect the inhibitory current response mediated by the GABAa receptor.
  • A-D There is no significant change in the inhibitory response current mediated by GABAa receptors in a midbrain dopaminergic nerve cell recorded by the example.
  • Figure 8 shows that in the midbrain dopaminergic neurons, GC-C activation can significantly increase mediated by the first type of metabotropic glutamate receptor (group I metabotropic glutamate receptor) or metabotropic acetylcholine receptor.
  • Excitatory response. (AD) G increases the excitatory response caused by DHPG.
  • A In a midbrain dopaminergic nerve cell, DHPG of ⁇ produces a more intense response in G of ⁇ ⁇ . The left panel shows the response of cells to DHPG before G is added. The right panel shows the response of cells to DHPG after G addition.
  • B The inward current caused by DHPG can be significantly increased by G. The left panel shows the response of cells to DHPG before G is added.
  • the reaction of cells to DHPG after G is added to the middle panel.
  • the right panel shows the response of cells to DHPG after washing G.
  • C A continuous reaction plot of cells to DHPG as shown in Figure B.
  • the left columnar graph shows the change of DHPG response before and after the addition of G/UG
  • the right columnar chart Indicates the addition of a reagent ODQ that inhibits the intersynaptic current reagent TTX and inhibits soluble guanylate cyclase. Changes in DHPG response of post-cells before and after G/UG addition.
  • EH GC-C activation increases the response caused by the ligand muscarine of the metabotropic acetylcholine receptor.
  • E UG can increase the cellular action potential response caused by muscarine.
  • the action potential recorded by the patch clamp on the left shows the excitatory response mediated by the metabotropic acetylcholine receptor in the cells recorded before the addition of UG.
  • the right panel shows the excitability mediated by the metabotropic acetylcholine receptor in the cells after the addition of UG. The sexual response increased.
  • Figure 9 shows that midbrain dopamine neurons of GC-C knockout mice exhibit normal intrinsic properties.
  • A, B A midbrain dopamine neuron recorded in GC-C knockout mice.
  • FIG. 10 shows that the potentiation of G/UG depends on the activity of GC-C and protein kinase G.
  • A-C G/UG Increased DHPG response is dependent on GC-C.
  • A An example demonstrates that a midbrain dopamine cell recorded in a GC-C knockout mouse is unable to increase its response to DHPG by UG.
  • B A graph of the response of the same cells to DHPG shown in A.
  • D-F G/UG increase reaction was eliminated by Rp-8-pCPT-cGMPS.
  • Figure 1 is a schematic diagram of the device for maintaining and monitoring the regular activities of animals R for a long time. The figure shows the device that is suitable for single animal activity.
  • Figure 12 is a schematic diagram of the odor adaptation test device and the experimental flow arrangement.
  • the first four odors used were Amyl Acetate, and the fifth test smell was Acetophenone.
  • Figure 13 is a picture of the actual animal being collected during the experiment. In the middle is the exposed centrifuge tube cover, and three small holes are dug in the cover to facilitate the evaporation of the odor.
  • Figure 14 is a schematic diagram of the device used for the go/no test and the experimental flow arrangement.
  • A Schematic diagram of the device.
  • B Experiment Process arrangement. The red bar indicates the "go" training unit, the corresponding sound stimulus is S+, the 3kHzo blue bar indicates the "not going" training unit, the corresponding sound stimulus is S -, the 15kHzo water droplet represents the reward, and the lightning represents the electric shock penalty.
  • Figure 15 is a timing diagram of the components in a single training unit in the first stage.
  • the arrow shows the mouse probe time, and the horn shows the sound start time.
  • the previous line indicates the start and end of the sound signal, and the next line indicates the start and end of the action time window.
  • Figure 16 is a timing diagram of the components in a single training unit in the second phase and the test phase.
  • Upper column Timing in a single unit in the second phase.
  • Lower bar Timing within a single unit during the test phase.
  • Figure 17 shows that the GC-C knockout mice exhibit a hyperactivity behavior defect similar to ADHD.
  • A Long-term monitoring revealed that the level of autonomic exercise in GC-C knockout mice was significantly higher than in wild mice when they were in the dark phase of the light/dark cycle. (*, p ⁇ 0.05; t-test, 5 in GC-C knockout mice and 5 in wild type and 5 in wild type)
  • B GC-C knockout mice in an adapted environment Got a lot. The horizontal autonomous movement of the animals in the new market is recorded by an infrared camera for 4 hours (one point every ten minutes).
  • Figure 18 shows that GC-C knockout mice exhibit impaired adaptability similar to ADHD.
  • the odor-adaptability of GC-C knockout mice was impaired.
  • Amyl acetate was used as the odor in the first four units, and acetophenone was used as the test odor in the fifth unit.
  • Right column The time to explore odor in GC-C knockout mice was significantly longer than that in wild type (*, p ⁇ 0.05; **, p ⁇ 0.01; t-test; 8 GC-C knockout mice, wild type 6).
  • Left column GC-C knockout mice also showed significant loss of adaptability.
  • Figure 19 shows a similar learning curve for wild-type mice and GC-C knockout mice.
  • the red curve is the learning curve for GC-C knockout mice.
  • the black curve is the learning curve for wild type mice.
  • the number of X axes is multiplied by 100 for the number of training units, and the y axis is the correct rate. Both mice achieved a 90% correct rate (no significant difference) after approximately 1500 training units.
  • Figure 20 shows the impulsiveness and maintenance of attention in GC-C knockout mice (1).
  • A Schematic diagram of the training method of the first stage and the hydrophobic activity corresponding to the sound stimulation after the GC-C knockout mouse and the wild type were learned in the first stage. The drowning activity is represented by a logic circuit signal, where a high level signal indicates that water is being drained.
  • B GC-C knockout mice stopped significantly longer than wild-type, indicating impaired behavioral inhibition and impulsivity (***, p ⁇ 0.001; t-test; GC-C KO 6 Only, wild type 10).
  • Figure 21 shows the impulsive and maintenance deficits of GC-C knockout mice (2).
  • the mice were asked to wait for a random delay of up to 2 seconds before the start of the stimulation and reaction time window.
  • GC-C knockout mice showed significantly higher rates of abandoning the training unit before the start of stimulation (A: **, p ⁇ 0.01; t-test) and a lower correct response rate than wild type (B : **, p ⁇ 0.01; t-test; 6 GC-C KO, 7 wild-type), indicating that they have poor ability to maintain attention.
  • Figure 23 is a dose-dependent effect of amphetamine on autonomic movement in mice.
  • Low doses of amphetamine (1 mg/kg body weight) reduced the level of autonomic exercise in GC-C knockout mice (analysis of variance in the first 70 minutes p ⁇ 0.001, 6 animals).
  • Figure 24 is a dose-dependent effect of amphetamine on spontaneous motor movement in mice. In contrast, the same dose of amphetamine had no effect on the level of autonomic exercise in the wild type (12 animals).
  • Figure 25 shows that high doses of amphetamine enhance autonomic movement in GC-C knockout mice and wild-type.
  • the peak of exercise caused by different doses was averaged relative to the exercise level after each animal was injected with physiological saline.
  • the black curve is the dose-effect curve for GC-C knockout mice, and the gray curve is the dose-effect curve for wild type mice.
  • Figure 26 shows that PKG agonists can reduce the autonomic activity of GC-C knockout mice.
  • the autonomic activity of GC-C knockout mice in the new environment was reduced after injection of the PKG agonist (p ⁇ 0.001 for the first 70 minutes of variance analysis, 5 animals each).
  • the black curve is the autonomous activity curve of GC-C knockout mice after injection of 3mM 8-Br-cGMP, and the gray curve is the autonomous activity curve of GC-C knockout mice after injection of artificial cerebrospinal fluid.
  • the materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
  • the GC-C knockout mice used in this study were provided by Elizabeth Mann and Mitchell B. Cohen of the Children's Hospital of Cincinnati. The mouse terminates the original sequence of the GC-C gene by replacing it with a sequence encoding the minigene hypoxanthine phosphoribosyltransferase (HPRT) by homologous recombination in mouse embryonic stem cells.
  • HPRT minigene hypoxanthine phosphoribosyltransferase
  • the expression of GC-C at this position [Mann, EA, et al., Mice lacking the guanylyl cyclase C receptor are resistant to STa-induced intestinal secretion. Biochem Biophys Res Commun, 1997. 239(2): 463-466.
  • the TH-GFP transgenic mouse was constructed by Kazuto Kobayashi of Fukushima Medical University, which is a C57BL/6 background. Construction of the mouse First, a plasmid containing a green fluorescent protein coding sequence directed by the mouse tyrosine hydroxylase (TM) promoter promoter was constructed, and the plasmid was linearized and injected into the fertilized egg by pronuclear injection. In the pronucleus, the treated fertilized egg is finally implanted into the surrogate mother, and the progeny are screened to obtain a transgenic mouse that specifically expresses GFP in the cell expressing the TH protein.
  • TM mouse tyrosine hydroxylase
  • mice In this strain of mice, eGFP is specifically expressed under the guidance of the TH promoter, thereby labeling only dopamine neurons.
  • All wild type mice used in this study were C57BL/6 mice (provided by Beijing Vitalriver Laboratory Animal Co., Ltd.) except for the special instructions.
  • the above-mentioned TH-GFP transgenic mice and GC-C knockout mice were all C57BL/6 backgrounds, raised and propagated in the SPF animal room of the Beijing Institute of Life Sciences, and were taken out until the experiment.
  • 10x recording of artificial cerebrospinal fluid sodium chloride 125 mM, potassium chloride 2.5 mM, calcium chloride dihydrate 2 mM, Magnesium chloride hexahydrate 1.3 mM, sodium dihydrogen phosphate 1.3 mM, sodium ascorbate L3 mM, sodium pyruvate 0.6 mM.
  • 100 mL of the stock solution was prepared to prepare a 100 mL solution, and sodium hydrogencarbonate and anhydrous glucose were added to bring the final concentrations to 25 mM and 10 mM, respectively, and the osmotic pressure was adjusted to be consistent with the former.
  • Perfusion solution sucrose, sodium chloride 1 19 mM, potassium chloride 2.5 mM, calcium chloride dihydrate O.lmM, magnesium chloride hexahydrate 4.9 mM, sodium dihydrogen phosphate lmM, sodium bicarbonate 26.2 mM, anhydrous glucose 1.25 mM, Sodium ascorbate lmM, kynuric acid 3 mM.
  • the prepared perfusion solution is dispensed in a volume of 50 ml and stored at -20 ° C, and can be repeatedly frozen and thawed.
  • Drugs guanylin (1 ⁇ ), ODQ (10 ⁇ ), 8-Br-cGMP (200 ⁇ ), Rp-8pCPT-cGMPS (10 ⁇ ), and ⁇ 5823 (2 ⁇ ) were purchased from BIOMOL; uroguanylin ( ⁇ ⁇ ) was purchased from Peptide; ⁇ ( ⁇ ⁇ ) and picrotoxin (10 ( ⁇ M) were purchased from Sigma; the original stock solution was diluted with artificial cerebrospinal fluid and added by circulation.
  • DHPG muscarine (50 ⁇ ) ⁇ (17.5 ⁇ ) and muscimol (50 ⁇ ) were purchased from Sigma, and were diluted with artificial cerebrospinal fluid in the experiment and given by the eight-channel rapid micro-dosing system (eight-channel rapid micro-dosing system was purchased from Wuhan 100). Shikang Biotechnology Co., Ltd.) The micro-portion is about 500 ⁇ from the cells. All the above drug storage solutions are dissolved in pure water or high-concentration DMSO according to the solubility characteristics of the drug to 1000 times or 2000 times the concentration of -20. Store at °C or -80 °C.
  • the electrode used in the patch clamp recording technique was a borosilicate glass electrode with a filament produced by Sutter Instruments, which had an outer diameter of 1.2 mm and an inner diameter of 0.69 mm.
  • the electrode was drawn using a P97 microelectrode puller (sutter instrument) to ensure a tip outer diameter of 2.6 ⁇ m.
  • the specific formula of the electrode liquid is as follows: Electrolyte internal liquid component, hydrochloric acid potassium 1 15 mM, hydroxyethyl piperazine ethanesulfonic acid 40 mM, magnesium chloride 5 mM, ethylene glycol tetraacetic acid 10 mM, potassium chloride 6 mM (pH 7.2- 7.4), store at -20 ° C.
  • the nystatin stock solution should be prepared on the day of the experiment, and the concentration is 25mg/ml. When using, add the electrode solution to the final concentration of 0.05 mg/ml-lmg/ml, taking care to avoid light.
  • the immunohistochemistry was as follows: The mice were deeply anesthetized with an excess of pentobarbital, then placed in a tray, and the entire blood circulation system was perfused with physiological saline. Specifically, a small needle injected with physiological saline is inserted from the right ventricle, and the pulmonary vein connected to the left atrium is cut. The pre-cooled physiological saline was perfused at a rate of about 2 ml per minute to allow systemic blood to flow out from the pulmonary veins. After the replacement was cleaned, it was perfused with pre-cooled phosphate buffer containing 4% paraformaldehyde until the mice were all stiff. Air bubbles should be avoided throughout the process.
  • the mouse brain was carefully dissected with small scissors and forceps, immersed in approximately 6 ml of 4% paraformaldehyde-containing phosphate buffer, fixed for 4 hours, and then dehydrated overnight with phosphate buffer containing 30% sucrose. After the brain was completely dehydrated, it was sectioned using a cryostat (Leica CM1900).
  • the specific method is as follows: First, the forebrain part of the brain is roughly removed, the midbrain is retained, and the midbrain is embedded with an embedding agent (OCT) and frozen in a frozen section of the -20 ° C. After being completely frozen and fixed, the brain slices were cut into 20 ⁇ using a microtome, and the brain slices were immersed in citrate buffer (PBS).
  • PBS citrate buffer
  • the prepared brain slices were washed three times with phosphate buffer, and the OCT residue was completely removed at intervals of 5 minutes. The non-specific site was then blocked with a phosphate buffer containing 10% calf serum and 0.1% triton-X for 1 hour.
  • the sheep-derived GC-C antibody (purchased from Santa Cruz Biotechnology, inc.) was diluted with a blocking solution at a ratio of 1:1000, and placed on a brain slice and incubated for 4 hours at 4 ⁇ . After the primary antibody was incubated, it was washed three or four times with phosphate buffer for 5 minutes each time.
  • the brain was incubated with the brain slices for two hours at room temperature with Cy3-donkey anti-goat (1:500, Jackson Immunoresearch). It was then washed three times with phosphate buffer again, 5 minutes apart.
  • the stained brain slices were plated on glass slides, and dried and visualized with a 50% glycerol seal containing DAPI. The slides were stored at 4 °C.
  • the pre-fixation, dehydration, and sectioning methods for in situ hybridization are the same as immunohistochemistry.
  • the treated brain slices were pretreated with a transcribed GC-C probe, a 740-nucleotide RNA single strand containing a sorghum marker, and hybridized at 64 °C for more than 16 hours. After elution, the treated brain slices were incubated with an anti-digoxigenin antibody ligated with alkaline phosphatase, and then developed with the substrate NBT/BCIP.
  • the midbrain immunohistochemistry results of normal mice showed that a large amount of GC-C was expressed on neurons in the VTA/SNc nucleus of the mouse midbrain (as shown in Fig. 1A, D, G), which is related to GC.
  • the results of RNA in situ hybridization by -C were consistent (as shown in Figure 2).
  • Careful observation of the staining signal mainly exists in the cell body and dendrites, but the Striatum nucleus mainly projected by the cells in the VTA/SNc nucleus is not.
  • the midbrain VTA/SNc nucleus contains a large number of dopamine projection neurons and inhibitory local neurons.
  • TH Tyrosine hydroxylase
  • the perforated patch clamp technique was used to clean the circulation tube of artificial cerebrospinal fluid with pure water before the start of the experiment. It was then replaced with artificial cerebrospinal fluid recorded with 95% oxygen and 5% carbon dioxide, and the circulation rate was adjusted to approximately 2 ml/min. Turn on the resistance heating fin wound around the inlet loop and adjust the temperature of the circulating solution to 32 °C.
  • the well-incubated brain slices were inhaled into a small tank filled with artificial cerebrospinal fluid and pressed with a platinum ring wrapped with nylon filaments.
  • the digital signal is monitored by Clampex 9 during recording, and the current or voltage stimulation of the cells can also be performed by editing the relevant program in Clampex 9.
  • the brain slices were prepared as follows: Prepare the ice cubes before preparation for slicing, and pre-cool the surgical instruments on ice.
  • the perfusion solution and section were ice bathed with artificial cerebrospinal fluid and filled with 95% oxygen and 5% carbon dioxide.
  • Approximately 200 ml of artificial cerebrospinal fluid was taken for recording, and a strainer was placed in the middle and incubated at 34 ⁇ .
  • the vibration frequency of the instrument is usually set at 8-9 when slicing, and the feed speed is generally set at 2-3.
  • the cut brain slices were transferred to the artificial cerebrospinal fluid at 34 ° C and filled with 95% oxygen and 5% carbon dioxide for at least 1 hour. .
  • the perforated patch clamp was used to record the midbrain dopamine neurons in normal adult mice.
  • the healthy cells were selected and stably recorded for more than 20 minutes.
  • the GC-C ligand guanylin (G) was added to the circulating solution at a final concentration of ⁇ .
  • Or uroguanylin (UG) for more than fifteen minutes, observe changes in cell current and resistance. Twenty dopamine cells recorded in the statistics showed no significant changes in cell current or resistance (as shown in Figure 5), indicating that GC-C activation could not open the ion channels on the cells and could not affect the dopamine neurons themselves. Basic characteristics of electrophysiology.
  • ⁇ -aminobutyric acid a (GABAa) receptor blocker picrotoxin was added to the artificial cerebrospinal fluid, and the cells were clamped at -60 mv to ensure that the recorded postsynaptic current was mainly caused by ⁇ .
  • GABAa ⁇ -aminobutyric acid a
  • DHPG ligand of metabotropic glutamate receptors
  • the frequency of cell excitability is shown in Figure 8A.
  • the specific experimental methods are as follows: Select healthy midbrain dopamine neurons, record the neurons using puncturing with a perforated patch clamp, clamp the cells to -60nw, record stably for about 10 minutes, and then switch to current clamp. Mode, giving the cells about -50pA of current, to ensure that the cells have no spontaneous discharge response.
  • the DHPG of ⁇ ⁇ was sprayed to the cells by a pressure system at a position of about 500 ⁇ m from the neurons, and the administration time of the pressure system was controlled by a computer program to be 2 s, thereby recording the excitatory response in the left image of A.
  • the administration was repeated three times, and each time interval was 5 minutes, the stability reaction as shown in the left figure was obtained.
  • ⁇ ⁇ G was added to the artificial cerebrospinal fluid in which the brain slices were incubated, and the response of the cells to DHPG was continuously recorded during the process. After about 10 minutes of G addition, the response of the neuron to DHPG became a pattern as shown on the right. .
  • G or UG can significantly increase the inward current caused by DHPG (increased by nearly 70%, as shown in Figure 8 B-D), and this effect can be reversed without G or UG.
  • the specific experimental methods were as follows: The healthy midbrain dopamine neurons were selected, and the neurons were recorded with a puncturing plaque using a perforated patch clamp, and the cells were clamped to -60 mv and stably recorded for more than 10 minutes.
  • the DHPG of ⁇ is injected into the cell by the pressure system at a position of about 800 ⁇ m from the neuron, and the administration time of the pressure system is controlled by a computer program to be 12 s, thereby recording the excitability of about ⁇ . Inward current.
  • GABA neurons in VTA/SNc express sGC, they can produce cGMP, which affects the electrical activity of peripheral dopamine neurons [Nugent, FS, EC Penick, and JA Kauer, Opioids block long-term potentiation of inhibitory synapses. Nature, 2007 446 (7139): 1086-1090 ⁇ ].
  • a 30 ⁇ m muscarine was sprayed onto the cells by a pressure system at a position of about 500 ⁇ m from the neurons, and the administration time of the pressure system was controlled by a computer program to be 6 s, thereby recording the excitatory response in the left panel of the E map.
  • the administration was repeated three times, and each time interval was 5 minutes, the stability reaction as shown in the left figure was obtained.
  • UG of ⁇ was added to the artificial cerebrospinal fluid in which the brain slices were incubated, and the response of the cells to muscarine was continuously recorded during this process. After about 10 minutes of UG addition, the response of the neuron to muscarine became the pattern shown in the right panel of E.
  • muscarine was sprayed onto the cells by a pressure system at a position of about 500 ⁇ m from the neurons, and the administration time of the pressure system was controlled by a computer program to be 5 s, thereby recording an excitatory introversion of about 100 pA. Current. Repeated administration 4 times, each time interval of 5 minutes, can obtain a relatively stable inward current. Three such inward currents are averaged to obtain the reaction shown in the left diagram of F. Then, ⁇ ⁇ G was added to the artificial cerebrospinal fluid in which the brain slices were incubated, and the response of the cells to muscarine was continuously recorded during the process.
  • G/UG enhances the excitatory response mediated by the first type of metabotropic glutamate receptor (I. metabotropic glutamate receptor) or metabotropic acetylcholine receptor depends on GC- Activation of C
  • GC-C knockout mice were used as experimental animals, and the midbrain dopamine neurons were detected by perforated patch clamp technique.
  • the specific method is to rapidly separate the mouse brain in a low temperature environment, and use a vibrating slicer to cut a horizontal brain slice with a thickness of 300 ⁇ m, incubate in artificial cerebrospinal fluid, and select midbrain dopamine neurons to use nystatin which forms micropores on the cell membrane. Patch clamp recording. It was found that the dopaminergic neurons of GC-C knockout mice were not significantly different in morphology from wild-type mice, and the observed discharge frequency was also consistent with that of common dopamine cells, and in voltage patch clamp mode.
  • KT5823 an inhibitor of selective functional subunits of protein kinase G.
  • Example 4 Comparative study of behavioral defects of ADHD in GC-C knockout mice and humans
  • Animal behavior research methods include the following: 1. Long-term continuous maintenance and monitoring of animal daily activities: Devices that can continuously maintain and monitor animal daily activities (as shown in Figure 11) can provide fully enclosed, non-interfering for experimental animals.
  • the living space can automatically control the supply of drinking water and food, conveniently set the light and dark rhythm in the enclosed space, and record its daily movement with an infrared camera. After the processing of the distance recording and analysis software, the observed animal can be calculated. Behavioral data such as the level of autonomous exercise, time and number of sleeps, and changes in cycle rhythm.
  • 2. Market test The site used for the open field test is a rectangular wooden box of 50*30 cm, 70 cm high, which contains litter and feed, and a water bottle is fixed on the wall.
  • An infrared camera was placed at a height of about 1.5 m above the wooden box to record the mouse's autonomous movement.
  • the camera was connected to a computer, and the data was collected and analyzed by software similar to that used for long-term monitoring.
  • the room under test is always under an inverted 12-hour alternating light, maintaining good ventilation and shielding.
  • the animals to be tested were pre-conditioned in the room for 4-7 days and then adapted to more than 4 hours in the wooden box.
  • the daily dosing test was started one hour after the light was turned from dark to dark. 3.
  • Odor adaptation test The test site is an opaque cylinder with a height of 30 cm and a diameter of 30 cm. There is a litter and feed in the cylinder, and a water bottle on the wall.
  • the cylinder frame In the center of the bottom of the cylinder is a small hole with a diameter of about 2 cm.
  • the cylinder frame is about 1 meter above the ground and has a bracket below it that just supports a 15 ml centrifuge tube head exposed from a small hole in the bottom of the tube.
  • Above the cylinder is an infrared camera that records the mouse's odor exploration during the experiment.
  • the odour diluted with mineral oil is contained in a 15 ml centrifuge tube and can be volatilized through a small hole drilled in the tube cover.
  • the mice were placed in a cylinder to acclimate to the environment one day before the test. The test room has been in reverse for 12 hours Maintain good ventilation and shielding for the light.
  • the test takes place in the first half of the dark period.
  • the small tube containing amyl acetate was first taken out from the hole in the bottom of the tube and held for 2 minutes.
  • the exploration of the mouse was taken and the odor was removed. Thereafter, the action was repeated every ten minutes for a total of four times, and the fifth time the test odor was changed to acetophenone (as shown in Figure 12). Note that proper dilution ensures that the vapor pressure of the latter odor is equal to the previous scent.
  • the time of the animal's exploration time, the number of explorations, and the interval of each exploration in the process of stimuli' stimuli are counted by manual timing.
  • Exploring the odor is defined as the tip of the mouse's nose close to 1 cm of the orifice (as shown in Figure 13). 4, go / no behavior paradigm: There is a hole on the wall of the training box that only allows the mouse mouth to explore. There are infrared transceivers on both sides of the hole to determine whether the mouse is in the past. A metal faucet is connected to the sensing circuit directly below the outside of the hole. The circuit records the signal when the mouse fills the nozzle. The faucet is also connected to a water-filled container and is controlled by a solenoid valve. The bottom of the training box is a shock plate that is connected to a maximum of 60 volts DC power. There is a speaker outside the training box to provide signals of 3K Hz and 15K Hz.
  • the speaker, shock plate and solenoid valve are controlled by software developed by our laboratory (as shown in Figure 14A).
  • Adult mice were deprived of drinking water one day prior to training and then placed in a training box. Throughout this training they must learn to get drinking by distinguishing the sound signals they hear.
  • the whole training process is formed by connecting the de-units and the non-de-units arranged in a pseudo-random manner. The two units appear equally many times (as shown in Figure 14B). Each unit begins with the mouse heading through the hole in the wall. After that, the sound is stimulated for 50-100 milliseconds and lasts for 1.2 seconds. 0.2 seconds after the start of the sound ; start the action time window, and finally the window is closed with the sound (as shown in Figure 15).
  • GC-C knockout mice and wild-type mice were tested for odor adaptation according to the animal behavior study method described above for "odor adaptation test". The results showed that the GC-C gene was compared with wild type mice. The time to knock out mice to explore odor was significantly longer than that of wild-type mice; GC-C knockout mice also showed significant loss of adaptability. This result indicates that the odor adaptability of GC-C knockout mice is impaired (as shown in the figure). 18)).
  • GC-C knockout mice and wild-type mice were subjected to attention test experiments according to the above animal behavior research method of "go/no-behavior" to detect GC-C knockout mice. Attention deficit. We first deprive them of drinking water and then train them to lick water based on the sound signals they get. If you hear a 3KHz sound stimulus, then you can get a little water as a reward, and if you hear a 15KHz sound stimulus, then the drowning will get a mild electric shock and a period of refractory period as a punishment. (As shown in Figure 14). At the beginning of the training, after the sound stimulation started, the mice had a period of 200 milliseconds to judge the type of stimulation (as shown in Figure 15).
  • ADHD attention deficit hyperactivity disorder
  • the probe used for intracranial microdialysis was CMA-7MD from CMA Microdialysis, with a membrane length of 1 mm and a cut-off size of 6 kilodaltons.
  • the perfusate was collected every 30 minutes, and 2 ⁇ l of 0.2 mol of perchloric acid was added to the collection tube in advance. Four consecutive samples were classified as one tube and frozen at -80 degrees.
  • the animals were injected with a lethal dose of pantobarbital, and the position of the probe was examined by coronal sectioning.
  • the determination of dopamine levels in microdialysis samples was performed using an electrochemical detector coupled to high performance liquid chromatography.
  • the BASi LC-4C type detector was used in the experiment.
  • Melted samples and standards 50 microliters
  • the dopamine elution time in this system is approximately 6 minutes.
  • human ADHD can be low-dose rather than high-dose neurostimulators amphetamine and its derivatives. Treatment, these drugs can increase the extracellular dopamine concentration in the brain by increasing dopamine release and inhibiting its recovery [References: Giros, B., et al., Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature , 1996. 379 (6566): 606-612. and Spencer, T., et al., Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry, 2001.
  • the intracranial administration method is as follows: The animal is anesthetized with discobarbital, and a bilateral long-term indwelling drug delivery catheter is implanted on the head, and the inner tube is positioned in the VTA/SNc region (the front side is 3 mm rearward, side) To 1.0 mm, 4.2 mm from the brain plane down). After a week of rest, a single GC-C knockout mouse was placed in a fresh test site, 8-Br-cGMP (0.5 ⁇ l per side, administered at a concentration of 3 mmol per liter, dissolved in ACSF) Or ACSF (as a control) was injected directly into VTA/SNc through a bilateral inner tube at a rate of 0.1 microliters per minute. Autonomous movement of the animals was started five minutes after the injection. At the end of each experiment, the animals were injected with a lethal dose of discobarbital, and the position of the probe was examined by coronal sectioning.
  • the present invention discloses for the first time that GC-C is specifically expressed on midbrain dopamine neurons; GC-C receptor activation can enhance the first type of metabotropic glutamate receptor (group I metabotropic glutamate receptor) And metabolic acetylcholine receptor-mediated excitatory responses.
  • group I metabotropic glutamate receptor group I metabotropic glutamate receptor
  • metabolic acetylcholine receptor-mediated excitatory responses The inventors of the present invention found that the behavioral deficit of GC-C knockout mice is very similar to that of human ADHD and can be improved by the treatment of human ADHD.
  • GC-C knockout mice were used as animal models of ADHD, and these mice were healthier than the previous typical SDHD animal model of spontaneously hypertensive rats (SHR).
  • the GC-C knockout mouse model can further be used to screen for the prevention and/or treatment of diseases associated with midbrain dopamine neurons, particularly for the prevention and/or treatment of human ADHD.
  • GC-C knockout mice provide a good opportunity for further study of the relationship between GC-C and midbrain dopamine neuron-associated diseases. More importantly, the experiments of the present invention demonstrate that the activity of the midbrain dopamine neuron can be selectively modulated by controlling the GC-C/PKG signaling pathway.
  • Efforts to develop agonists or inhibitors acting on the GC-C/PKG signaling pathway will likely lead to the development of new therapeutic approaches to treat those mental disorders associated with the midbrain dopamine system, such as schizophrenia, attention deficit hyperactivity disorder , Parkinson's disease and drug addiction.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de substances ciblant la voie de signalisation GC-C dans le diagnostic et le traitement de maladies des neurones dopaminergiques mésencéphaliques. Une des utilisations décrites par la présente invention est le procédé de génération d'un modèle animal du trouble d'hyperactivité avec déficit de l'attention à l'aide du gène GC-C comme cible. Le procédé comprend les étapes suivantes : le gène GC-C du mammifère cible est inactivé et l'animal au gène GC-C inactivé obtenu est le modèle animal du trouble d'hyperactivité avec déficit de l'attention. Le modèle animal du trouble d'hyperactivité avec déficit de l'attention peut être utilisé pour cribler des produits pour la prévention et/ou le traitement de maladies associées à un système dopaminergique mésencéphalique.
PCT/CN2011/001209 2011-07-25 2011-07-25 Utilisation de substances ciblant la voie de signalisation gc-c dans le diagnostic et le traitement de maladies des neurones dopaminergiques mésencéphaliques WO2013013338A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/001209 WO2013013338A1 (fr) 2011-07-25 2011-07-25 Utilisation de substances ciblant la voie de signalisation gc-c dans le diagnostic et le traitement de maladies des neurones dopaminergiques mésencéphaliques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2011/001209 WO2013013338A1 (fr) 2011-07-25 2011-07-25 Utilisation de substances ciblant la voie de signalisation gc-c dans le diagnostic et le traitement de maladies des neurones dopaminergiques mésencéphaliques

Publications (1)

Publication Number Publication Date
WO2013013338A1 true WO2013013338A1 (fr) 2013-01-31

Family

ID=47600434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001209 WO2013013338A1 (fr) 2011-07-25 2011-07-25 Utilisation de substances ciblant la voie de signalisation gc-c dans le diagnostic et le traitement de maladies des neurones dopaminergiques mésencéphaliques

Country Status (1)

Country Link
WO (1) WO2013013338A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160067A1 (fr) * 2017-03-02 2018-09-07 Universiteit Van Amsterdam Augmentation spécifique de la synthèse de la dopamine par ciblage du récepteur de la guanylate cyclase 2c dans le traitement de la maladie de parkinson
CN115116561A (zh) * 2022-06-29 2022-09-27 南方医科大学南方医院 一种药物-靶蛋白-精神分裂症互作网络的构建方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101772513A (zh) * 2007-06-04 2010-07-07 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101772513A (zh) * 2007-06-04 2010-07-07 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STEPHEN L: "Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor.", KIDNEY INTERNATIONAL, vol. 65, 2004, pages 40 - 53 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160067A1 (fr) * 2017-03-02 2018-09-07 Universiteit Van Amsterdam Augmentation spécifique de la synthèse de la dopamine par ciblage du récepteur de la guanylate cyclase 2c dans le traitement de la maladie de parkinson
US20200009213A1 (en) * 2017-03-02 2020-01-09 Universiteit Van Amsterdam Specific Increase of Dopamine Synthesis THrough Targeting of the Guanylate Cyclase 2C Receptor in the Treatment of Parkinson's Disease
CN115116561A (zh) * 2022-06-29 2022-09-27 南方医科大学南方医院 一种药物-靶蛋白-精神分裂症互作网络的构建方法及其应用

Similar Documents

Publication Publication Date Title
Jaramillo et al. Novel Shank3 mutant exhibits behaviors with face validity for autism and altered striatal and hippocampal function
Mittag et al. Thyroid hormone is required for hypothalamic neurons regulating cardiovascular functions
Callaerts-Vegh et al. Concomitant deficits in working memory and fear extinction are functionally dissociated from reduced anxiety in metabotropic glutamate receptor 7-deficient mice
Michetti et al. The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations
Bhattacharya et al. Genetically induced retrograde amnesia of associative memories after neuroplastin ablation
Taylor et al. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse
Vyas et al. Influence of maternal zinc supplementation on the development of autism-associated behavioural and synaptic deficits in offspring Shank3-knockout mice
Luo et al. NMDA receptors on non-dopaminergic neurons in the VTA support cocaine sensitization
Bertocchi et al. Voltage-independent GluN2A-type NMDA receptor Ca2+ signaling promotes audiogenic seizures, attentional and cognitive deficits in mice
Kobayashi et al. Modest neuropsychological deficits caused by reduced noradrenaline metabolism in mice heterozygous for a mutated tyrosine hydroxylase gene
Liu et al. Activation and blockade of serotonin6 receptors in the dorsal hippocampus enhance T maze and hole-board performance in a unilateral 6-hydroxydopamine rat model of Parkinson's disease
Lee et al. Dietary zinc supplementation rescues fear-based learning and synaptic function in the Tbr1+/− mouse model of autism spectrum disorders
WO2013013338A1 (fr) Utilisation de substances ciblant la voie de signalisation gc-c dans le diagnostic et le traitement de maladies des neurones dopaminergiques mésencéphaliques
Krol et al. Two eARCHT3. 0 lines for optogenetic silencing of dopaminergic and serotonergic neurons
US8895511B2 (en) Use of sarcoplasmic CA2+-ATPase type 2 protein for diagnosing and treating learning or mental disorders
US20080051315A1 (en) Grp Receptor-Related Methods for the Treating and Preventing Fear-Related Disorders
Brandner Neuroligin-3 Modulates Opioid-Evoked Changes in Behavior and Brain Function
Wells The Role of Dysfunctional Subcortical Circuitry in Mouse Models of Developmental Disability
Yang Central Amygdala-Associated Behavioural Phenotypes in a Gain-Of-Function Voltage-Gated Sodium Channel NaV1. 5 Mouse Model
Zike Investigating the Role of Obsessive-Compulsive Disorder Candidate Gene SLC1A1 in Basal Ganglia and Repetitive Behavior
Vo Molecular mechanisms and therapeutic potential of inhibitory G protein signaling in anxiety disorders
Maksymetz Potentiating M1 and mGlu1 receptors to modulate prefrontal cortical dysfunction in psychiatric diseases
Mahabir The Effect of Embryonic Alcohol Exposure on Brain Function and Behavior in Zebrafish Strains
Vahid-Ansari Altered serotonin regulation in genetic and post-stroke models of anxiety and depression
Tickerhoof She Loves Me, He Loves Me Not: Regulation of Social Conflict-Induced Changes in Social Behavior and Attachment by the Amygdala and Extended Amygdala

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11869966

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11869966

Country of ref document: EP

Kind code of ref document: A1